Tempest Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Tempest Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $295.0K | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $653.0K | Mar 15, 2018 |
| FY2017 | Dec 31, 2015 | $277.0K | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $0 | Mar 2, 2017 |
| FY2015 | Dec 31, 2013 | $0 | Feb 26, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.26M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($41.84M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($29.49M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($35.71M) | Mar 19, 2024 |
| FY2021 | Dec 31, 2021 | ($28.30M) | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | ($19.21M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($44.57M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($27.19M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($84.58M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($82.26M) | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.58M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($42.03M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($29.16M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($34.64M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($26.99M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($19.30M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($45.40M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($26.87M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($84.33M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($81.01M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $18.34M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $21.64M | Mar 15, 2018 |
| FY2017 | Dec 31, 2015 | $18.43M | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $21.78M | Mar 2, 2017 |
| FY2015 | Dec 31, 2013 | $15.80M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $6.32M | Mar 16, 2015 |
| FY2013 | Dec 31, 2011 | $1.17M | Feb 27, 2014 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $27.74M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $49.22M | Mar 15, 2018 |
| FY2017 | Dec 31, 2015 | $51.59M | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $26.15M | Mar 2, 2017 |
| FY2015 | Dec 31, 2013 | $13.33M | Feb 26, 2016 |
| FY2014 | Dec 31, 2012 | $7.21M | Mar 16, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.82M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($33.03M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($27.36M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($31.07M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($25.96M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($19.02M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($41.22M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($23.65M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($20.34M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($61.73M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $435.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $170.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $562.0K | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $135.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $50.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $397.0K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $36.0K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $4.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.59M | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.93M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $41.49M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $51.60M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $46.09M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $73.24M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $22.86M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $74.97M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $84.07M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $19.81M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $122.54M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.26M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $22.36M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $24.84M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $27.98M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $37.12M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $4.95M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $15.10M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $10.95M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $4.83M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $14.33M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.67M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $19.13M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $26.77M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $18.11M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $36.12M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | ($68.79M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | ($50.36M) | Mar 29, 2022 |
| FY2019 | Dec 31, 2018 | $70.95M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($130.69M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $108.22M | Mar 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($233.37M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($207.11M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($165.26M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($135.77M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($100.06M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($71.76M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($208.65M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($164.09M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($136.89M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($250.18M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.71M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $30.27M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $39.23M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $31.23M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $51.83M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $18.82M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $62.48M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $73.29M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $17.58M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $43.93M | Mar 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.40M | Mar 27, 2025 |
| FY2023 | Dec 31, 2023 | $10.50M | Mar 19, 2024 |
| FY2022 | Dec 31, 2022 | $10.40M | Mar 22, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (19) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (7) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | (41) | Mar 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (19) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (3) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (7) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | (41) | Mar 29, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.93M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 3.38M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 22.05M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 10.52M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 6.91M | Mar 22, 2023 |
| FY2020 | Dec 31, 2020 | 19.00M | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | 18.27M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 13.36M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 246,347 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 35.64M | Mar 15, 2018 |